The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
Open accessAbstract
Natural killer (NK) cells are lymphocytes of the innate immune response characterized by their role in the destruction of tumor cells. Activation of NK cells depend on a fine balance between activating and inhibitory signals mediated by different receptors. In recent years, a family of paired receptors that interact with ligands of the Nectin/Nectin-like (Necl) family has attracted great interest. Two of these ligands, Necl-5 (usually termed CD155 or PVR) and Nectin-2 (CD112), frequently expressed on different types of tumor cells, are recognized by a group of receptors expressed on T and NK cells that exert opposite functions after interacting with their ligands. These receptors include DNAM-1 (CD226), TIGIT, TACTILE (CD96) and the recently described PVRIG. Whereas activation through DNAM-1 after recognition of CD155 or CD112 enhances NK cell-mediated cytotoxicity against a wide range of tumor cells, TIGIT recognition of these ligands exerts an inhibitory effect on NK cells by diminishing IFN-γ production, as well as NK cell-mediated cytotoxicity. PVRIG has also been identified as an inhibitory receptor that recognizes CD112 but not CD155. However, little is known about the role of TACTILE as modulator of immune responses in humans. TACTILE control of tumor growth and metastases has been reported in murine models, and it has been suggested that it negatively regulates the anti-tumor functions mediated by DNAM-1. In NK cells from patients with solid cancer and leukemia, it has been observed a decreased expression of DNAM-1 that may shift the balance in favor to the inhibitory receptors TIGIT or PVRIG, further contributing to the diminished NK cell-mediated cytotoxic capacity observed in these patients. Analysis of DNAM-1, TIGIT, TACTILE and PVRIG on human NK cells from solid cancer or leukemia patients will clarify the role of these receptors in cancer surveillance. Overall, it can be speculated that in cancer patients the TIGIT/PVRIG pathways are upregulated and represent novel targets for checkpoint blockade immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524 · cited 5×
“The cytoplasmic tail contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoglobulin tail tyrosine (ITT)-like motif, which are highly conserved between mouse and human [41,51,75,76].”
BackgroundResultInfluentialEffectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Soriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., Cippitelli, M., Fionda, C., Petrucci, M. T., Guarini, A., et al. (2009) · Blood · doi:10.1182/blood-2008-08-173914 · Cited by 460
Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36022 · Cited by 347
Carlsten, M., Björkström, N. K., Norell, H., Bryceson, Y., van Hall, T., Baumann, B. C., Hanson, M., Schedvins, K., Kiessling, R., Ljunggren, H.-G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2264 · Cited by 234
Decreased expression of DNAM‐1 on NK cells from acute myeloid leukemia patients
Sanchez‐Correa, B., Gayoso, I., Bergua, J. M., Casado, J. G., Morgado, S., Solana, R., & Tarazona, R. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.15 · Cited by 228 · cited 2×
“Furthermore, the expression of DNAM-1 was decreased in NK cells from acute myeloid leukemia patients and it was negatively correlated with the expression of CD112 in blasts [43] supporting that DNAM-1 downregulation on NK cells in patients with cancer, is a consequence of the tumor burden.”
BackgroundResultSelf-citationMolecular pathways: targeting CD96 and TIGIT for cancer immunotherapy
Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W. L., & Smyth, M. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0933 · Cited by 223
Cited by
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
The cancer–natural killer cell immunity cycle
Huntington, N. D., Cursons, J., & Rautela, J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0272-z · Cited by 566
TIGIT as an emerging immune checkpoint
Harjunpää, H., & Guillerey, C. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13407 · Cited by 552
Vivier, E., Rebuffet, L., Narni-Mancinelli, E., Cornen, S., Igarashi, R. Y., & Fantin, V. R. (2024) · Nature · doi:10.1038/s41586-023-06945-1 · Cited by 467
Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity
Wang, J. X., Choi, S. Y. C., Niu, X., Kang, N., Xue, H., Killam, J., & Wang, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218363 · Cited by 460
Metadata
- Authors
- Sanchez-Correa, B., Valhondo, I., Hassouneh, F., Lopez-Sejas, N., Pera, A., Bergua, J. M., Arcos, M. J., Bañas, H., Casas-Avilés, I., Durán, E., Alonso, C., Solana, R., & Tarazona, R.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-06-23
- Volume
- 11
- Issue
- 6
- Pages
- 877
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2949403516
- Cited by
- 213
- References
- 10
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.